Arcellx Inc (ACLX)

$63.00 -0.82 (-1.28%)
Market Cap 3.47B
Revenue (ttm) 107.94M
Net Income (ttm) -107.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -99.45%
Debt to Equity Ratio 0.00
Volume 986,900
Avg Vol 760,720
Day's Range N/A - N/A
Shares Out 55.11M
Stochastic %K 26%
Beta 0.28
Analysts Strong Sell
Price Target $112.44

Company Profile

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 327 0630
Address:
800 Bridge Parkway, Redwood City, United States
JarvisFlow
JarvisFlow Jun. 17 at 12:00 PM
Citigroup has updated their rating for Arcellx ( $ACLX ) to Buy with a price target of 110.
0 · Reply
Ned_Nosurname
Ned_Nosurname Jun. 17 at 6:54 AM
$ACLX $GILD https://www.oncologypipeline.com/apexonco/eha-2025-arcellx-still-hopes-safety-will-trump-efficacy
0 · Reply
JarvisFlow
JarvisFlow Jun. 16 at 12:00 PM
HC Wainwright & Co. updates rating for Arcellx ( $ACLX ) to Buy, target set at 115.
0 · Reply
Falcones
Falcones Jun. 12 at 12:29 PM
$ACLX Just finished my DD. Taking a long position today at open! Pipeline with their lead product looks very promising!
0 · Reply
hbwalk2
hbwalk2 Jun. 4 at 4:33 PM
$ACLX 500 June 65 calls just traded. Oi is 1,100. No offsetting option trades detected. Interesting to see tomorrow is Oi shrinks
0 · Reply
hbwalk2
hbwalk2 Jun. 4 at 4:29 PM
$ACLX Is the company being cast into the cancer buyout club??
0 · Reply
hbwalk2
hbwalk2 Jun. 4 at 2:33 PM
$ACLX Hellooooooo…. this under-followed gem is about to rip higher on technicals
1 · Reply
LewisDaKat
LewisDaKat May. 31 at 2:25 PM
$ACLX News Article $ACLX How to Take Advantage of moves in (ACLX)https://marketwirenews.com/news-releases/how-to-take-advantage-of-moves-in-aclx--7286762345797005.html
0 · Reply
BillionerOfKing
BillionerOfKing May. 22 at 10:50 AM
$ACLX Biotech has been perking up and this chart looks like it’s winding for a move. Watching breakout levels. https://bit.ly/4keyPyA Note: I am not an advisor. Before investing, always do your own research first.
0 · Reply
PEROG
PEROG May. 21 at 1:47 PM
$ACLX updated data on safety leaked b4 EHA 6/14 oral presentation or wth is going on?
0 · Reply
Latest News on ACLX
Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

May 21, 2025, 4:00 PM EDT - 4 weeks ago

Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

May 14, 2025, 9:30 AM EDT - 5 weeks ago

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:00 PM EDT - 6 weeks ago

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

Apr 29, 2025, 11:45 AM EDT - 7 weeks ago

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

ISRG MASI MCK NTRA PEN TMO UNH

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Apr 29, 2025, 11:30 AM EDT - 7 weeks ago

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

BSX DHR GKOS INSM ISRG LLY RDNT

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

Mar 20, 2025, 4:00 PM EDT - 3 months ago

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month

Mar 18, 2025, 8:44 AM EDT - 3 months ago

Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month

Arcellx Impressive Safety Data Leaves Doubts

Mar 17, 2025, 11:27 AM EDT - 3 months ago

Arcellx Impressive Safety Data Leaves Doubts

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

Feb 27, 2025, 4:00 PM EST - 4 months ago

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 4:00 PM EST - 4 months ago

Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference

Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients

Dec 9, 2024, 7:50 AM EST - 7 months ago

Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

Dec 8, 2024, 11:00 PM EST - 7 months ago

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

Nov 7, 2024, 4:00 PM EST - 8 months ago

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

Nov 5, 2024, 9:00 AM EST - 8 months ago

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

Sep 10, 2024, 8:30 AM EDT - 10 months ago

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates

Aug 8, 2024, 4:00 PM EDT - 11 months ago

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates

Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market

Jun 26, 2024, 11:19 AM EDT - 1 year ago

Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

May 9, 2024, 4:05 PM EDT - 1 year ago

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

GILD

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

May 9, 2024, 4:05 PM EDT - 1 year ago

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

GILD

Arcellx Provides First Quarter 2024 Financial Results

May 9, 2024, 4:00 PM EDT - 1 year ago

Arcellx Provides First Quarter 2024 Financial Results

Arcellx to Participate in Two Upcoming Investor Conferences

May 7, 2024, 4:00 PM EDT - 1 year ago

Arcellx to Participate in Two Upcoming Investor Conferences

Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Apr 4, 2024, 4:00 PM EDT - 1 year ago

Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 20, 2024, 4:00 PM EDT - 1 year ago

Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference

Feb 29, 2024, 4:00 PM EST - 1 year ago

Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference

Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights

Feb 28, 2024, 4:00 PM EST - 1 year ago

Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights

Arcellx: Navigating The CAR T-Cell Revolution

Jan 30, 2024, 5:13 AM EST - 1 year ago

Arcellx: Navigating The CAR T-Cell Revolution

Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH

Dec 8, 2023, 4:00 PM EST - 1 year ago

Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH

Arcellx: A Strong Contender In The CAR-T Multiple Myeloma Market

Nov 15, 2023, 1:44 PM EST - 1 year ago

Arcellx: A Strong Contender In The CAR-T Multiple Myeloma Market

Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premium

Nov 15, 2023, 6:23 AM EST - 1 year ago

Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premium

GILD

Kite and Arcellx Announce Expansion in Strategic Partnership

Nov 15, 2023, 6:00 AM EST - 1 year ago

Kite and Arcellx Announce Expansion in Strategic Partnership

GILD

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

Nov 15, 2023, 6:00 AM EST - 1 year ago

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

GILD

Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights

Nov 13, 2023, 4:00 PM EST - 1 year ago

Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights

Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition

Nov 2, 2023, 9:00 AM EDT - 1 year ago

Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition

Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results

Aug 14, 2023, 4:00 PM EDT - 2 years ago

Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results

Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program

Jun 19, 2023, 7:46 PM EDT - 2 years ago

Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program

Arcellx Provides First Quarter Financial Results

May 8, 2023, 4:00 PM EDT - 2 years ago

Arcellx Provides First Quarter Financial Results

Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference

Apr 13, 2023, 4:01 PM EDT - 2 years ago

Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference

Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights

Mar 29, 2023, 4:01 PM EDT - 2 years ago

Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights

Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference

Feb 21, 2023, 4:00 PM EST - 2 years ago

Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference

Arcellx to Participate in Upcoming Investor Conferences

Feb 2, 2023, 4:00 PM EST - 2 years ago

Arcellx to Participate in Upcoming Investor Conferences

Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

Jan 30, 2023, 9:00 AM EST - 2 years ago

Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

GILD

Arcellx: The Gilead Deal Derisks And Proves Their Technology

Jan 9, 2023, 12:46 PM EST - 2 years ago

Arcellx: The Gilead Deal Derisks And Proves Their Technology

Gilead to co-develop Arcellx's multiple myeloma drug

Dec 9, 2022, 8:46 AM EST - 2 years ago

Gilead to co-develop Arcellx's multiple myeloma drug

GILD

Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

Dec 9, 2022, 8:17 AM EST - 2 years ago

Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

GILD

Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress

Dec 9, 2022, 8:17 AM EST - 2 years ago

Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress

Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma

Dec 9, 2022, 8:15 AM EST - 2 years ago

Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma

GILD

Arcellx Reports Third Quarter 2022 Financial Results and Business Progress

Nov 14, 2022, 4:00 PM EST - 2 years ago

Arcellx Reports Third Quarter 2022 Financial Results and Business Progress

Arcellx Announces Presentation of New Clinical Data from Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 64th ASH Annual Meeting and Exposition

Nov 3, 2022, 9:00 AM EDT - 2 years ago

Arcellx Announces Presentation of New Clinical Data from Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 64th ASH Annual Meeting and Exposition

Arcellx Announces Participation at the Morgan Stanley 20th Annual Global Healthcare Conference

Sep 7, 2022, 4:01 PM EDT - 3 years ago

Arcellx Announces Participation at the Morgan Stanley 20th Annual Global Healthcare Conference

JarvisFlow
JarvisFlow Jun. 17 at 12:00 PM
Citigroup has updated their rating for Arcellx ( $ACLX ) to Buy with a price target of 110.
0 · Reply
Ned_Nosurname
Ned_Nosurname Jun. 17 at 6:54 AM
$ACLX $GILD https://www.oncologypipeline.com/apexonco/eha-2025-arcellx-still-hopes-safety-will-trump-efficacy
0 · Reply
JarvisFlow
JarvisFlow Jun. 16 at 12:00 PM
HC Wainwright & Co. updates rating for Arcellx ( $ACLX ) to Buy, target set at 115.
0 · Reply
Falcones
Falcones Jun. 12 at 12:29 PM
$ACLX Just finished my DD. Taking a long position today at open! Pipeline with their lead product looks very promising!
0 · Reply
hbwalk2
hbwalk2 Jun. 4 at 4:33 PM
$ACLX 500 June 65 calls just traded. Oi is 1,100. No offsetting option trades detected. Interesting to see tomorrow is Oi shrinks
0 · Reply
hbwalk2
hbwalk2 Jun. 4 at 4:29 PM
$ACLX Is the company being cast into the cancer buyout club??
0 · Reply
hbwalk2
hbwalk2 Jun. 4 at 2:33 PM
$ACLX Hellooooooo…. this under-followed gem is about to rip higher on technicals
1 · Reply
LewisDaKat
LewisDaKat May. 31 at 2:25 PM
$ACLX News Article $ACLX How to Take Advantage of moves in (ACLX)https://marketwirenews.com/news-releases/how-to-take-advantage-of-moves-in-aclx--7286762345797005.html
0 · Reply
BillionerOfKing
BillionerOfKing May. 22 at 10:50 AM
$ACLX Biotech has been perking up and this chart looks like it’s winding for a move. Watching breakout levels. https://bit.ly/4keyPyA Note: I am not an advisor. Before investing, always do your own research first.
0 · Reply
PEROG
PEROG May. 21 at 1:47 PM
$ACLX updated data on safety leaked b4 EHA 6/14 oral presentation or wth is going on?
0 · Reply
hbwalk2
hbwalk2 May. 21 at 11:18 AM
$ACLX options premiums for June calls are pricey. Anyone know of there are any key dates coming before June 20?
1 · Reply
DiamondHandsBTW
DiamondHandsBTW May. 14 at 5:58 PM
$LEGN $ACLX news came out that’s why for the drop. Also to note they are getting a new HQ with long term lease hence lowers probability of M&A
0 · Reply
BellaDante5
BellaDante5 May. 7 at 2:24 PM
$MODD $BEAM $ACLX $OCGN $INSM You all checked out $MODD and what are trying to do in the insulin/diabetes space?
0 · Reply
svb64
svb64 May. 6 at 5:30 PM
$ACLX news?
1 · Reply
_www_larval_com_
_www_larval_com_ May. 6 at 5:17 PM
$ACLX has slipped -6% lower to -17% (~662Kv) a few minutes ago, 05/16 options, follow for more volatility.
0 · Reply
Armonica423
Armonica423 May. 6 at 1:48 PM
$ACLX CYDY
0 · Reply
justiceforb_85
justiceforb_85 Apr. 16 at 4:45 AM
$ACLX safety data appears to favor anito-cel versus ciltacabtagene autoleucel. However, cilta-cel is approved for earlier MM treatment. Is ACLX attempting to gain approval for earlier line of therapy?
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 26 at 1:01 PM
$ACLX Ddcars looking legit. Kite partnership validates tech. Watching closely for clinical updates on anito-cel. Potential game changer in myeloma treatment. insightful article: https://beyondspx.com/article/arcellx-inc-nasdaq-aclx-reimagining-cell-therapy-with-innovative-immunotherapies
0 · Reply
stockmando
stockmando Mar. 7 at 1:41 AM
$VOR $ACLX Not a major event, but who is following industry, might be interested. March 13, 11AM.
0 · Reply
Milanfinest
Milanfinest Mar. 4 at 11:34 PM
$ACLX i m the hero of this board!
0 · Reply
Milanfinest
Milanfinest Feb. 27 at 5:52 PM
$VRNA so no one follows me on $ACLX & $VKTX 😜🤌🏻🇮🇹🔪?
1 · Reply
Milanfinest
Milanfinest Feb. 22 at 1:48 AM
$ACLX 324 watchers🤣😅😅😅
1 · Reply